Laxatives 제대로 알기 ; 차세대 완하제 = Special Review : New Generation Laxatives

다국어 초록 (Multilingual Abstract)

A significant proportion of chronic constipation patients are dissatisfied with their treatment. Recently, a number of new medicationshave been introduced for patients refractory to conventional laxatives, such as prucalopride, lubiprostone, linaclotide, andelobixibat. Prucalopride is a novel gastrointestinal prokinetic agent that acts as a 5-hydroxytryptamine type 4 (5-HT4) agonist. Compared with older nonselective 5-HT4 agonists, the higher selectivity of prucalopride for 5-HT4 receptors can reduce the risk ofsignificant adverse cardiovascular events. Prucalopride improves stool frequency and consistency, and reduces the need for rescuemedications. Lubiprostone, a chloride channel activator, increases the secretion of intestinal fluid, improves the stool frequency andconsistency, and reduces straining. Linaclotide, a guanylate cyclase-C agonist, is effective in treating patients with chronic constipationand its effect on visceral sensitivity, as shown mainly in animal studies, provides an attractive pharmaceutical option for patients with irritable bowel syndrome with constipation. Elobixibat is an ileal sodium-dependent bile acid transporter inhibitor thatblocks the enterohepatic circulation of bile acids, increasing the bile acid concentration in the intestine, which accelerates colonictransit and softens the stool. A phase III trial of the treatment of chronic constipation and irritable bowel syndrome with constipationis underway. The clinical application of new-generation laxatives will contribute to the management of chronic constipation refractoryto conventional laxatives.

참고문헌 (Reference)

1 홍경섭, "만성변비 치료의 최근 동향" 대한소화기학회 64 (64): 148-153, 2014

2 Gershon MD, "The serotonin signaling system: from basic understanding to drug development for functional GI disorders" 132 : 397-414, 2007

3 Wald A, "The burden of constipation on quality of life: results of a multinational survey" 26 : 227-236, 2007

4 Jadav AM, "The association between prucalopride efficacy and constipation type" 17 : 555-559, 2013

5 Tack J, "Systematic review:cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders" 35 : 745-767, 2012

6 Vaandrager AB, "Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C" 230 : 73-83, 2002

7 Cuppoletti J, "SPI-0211activates T84 cell chloride transport and recombinant human ClC-2 chloride currents" 287 : C1173-C1183, 2004

8 Quigley EM, "Prucalopride: safety, efficacy and potential applications" 5 : 23-30, 2012

9 Ke M, "Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region:a randomized, double-blind, placebo-controlled study" 24 : 999-e541, 2012

10 Chaplin S, "Prucalopride (resolor):new treatment for chronic constipation" 21 : 24-29, 2010

11 Tack J, "Prucalopride (resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives" 58 : 357-365, 2009

12 Shailubhai K, "Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses" 58 : 2580-2586, 2013

13 Lembo AJ, "Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation" 56 : 2639-2645, 2011

14 Chey WD, "Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety" 107 : 1702-1712, 2012

15 Müller-Lissner S, "Levels of satisfaction with current chronic constipation treatment options in Europe-an internet survey" 37 : 137-145, 2013

16 Eutamene H, "Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain" 22 : 312-e84, 2010

17 Yiannakou Y, "Efficacy and safety of prucalopride in men with chronic constipation: a phase 3, randomized, double-blind, placebo-controlled trial [abstract]" 146 (146): S160-, 2014

18 Fukudo S, "Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebocontrolled and dose-finding study" 23 : 544-e205, 2011

19 Wong BS, "Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation" 106 : 2154-2164, 2011

20 Tack J, "Effect of prucalopride on symptoms of chronic constipation" 26 : 21-27, 2014

21 Andresen V, "Effect of 5days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome" 133 : 761-768, 2007

22 Quigley EM, "Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebocontrolled study" 29 : 315-328, 2009

23 Camilleri M, "Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation-follow-up of patients from the pivotal studies" 32 : 1113-1123, 2010

24 Johanson JF, "Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation" 27 : 685-696, 2008

25 Mendzelevski B, "Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo-and positive-controlled thorough QT study" 73 : 203-209, 2012

26 Chey WD, "A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation" 106 : 1803-1812, 2011

27 Jun DW, "A population-based study on bowel habits in a Korean community: prevalence of functional constipation and self-reported constipation" 51 : 1471-1477, 2006

28 Camilleri M, "A placebo-controlled trial of prucalopride for severe chronic constipation" 358 : 2344-2354, 2008

29 Müller-Lissner S, "A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation" 22 : 991-998, 2010

30 Rao S, "A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation" 107 : 1714-1724, 2012

31 De Maeyer JH, "5-HT4 receptor agonists: similar but not the same" 20 : 99-112, 2008